Immunoaffinity Chromatography Industry - Regional Synopsis
North America Market Analysis
The North America immunoaffinity chromatography market is poised to capture the largest share of 38.9%, rising at a CAGR of 7.7% during the forecast period, 2025-2037. The region’s wide presence of Medicare expansion and R&D dominance in this sector is a major contributor to this supremacy. For instance, in 2024, NIH allocated USD 2.6 billion for chromatography research and development. Besides, the Medicare spending on IAC-dependent drugs reached USD 1.3 billion in 2024, which is a 16% year-over-year increase reflecting the heightened demand. Leading firms such as Thermo Fisher and Bio-Rad are leading the automation adoption, positioning North America as a global leader in the market.
There is a huge opportunity for the immunoaffinity chromatography market in Canada, rising at a CAGR of 6.8%, owing to the federal and provincial healthcare investments. The presence of robust healthcare infrastructure and extensive government support is fostering a favorable business environment both for domestic and international firms. In this regard, Health Canada in 2024 assigned USD 3.3 billion for biologics, out of which 22% was directed towards purification tech. Besides, Ontario expanded its budget by 20% for IAC-based treatments, facilitating access to 200,000 patients. Moreover, the partnership tendency of CROs in the country reduces reliance on import costs by 16%.
Europe Market Statistics
Europe holds the second-largest share of 28.4% in the global immunoaffinity chromatography market, critically led by biosimilar adoption and strict regulatory standards. Price cap adjustments and the regional push towards automation, which cuts 32% labor costs, are further accelerating upliftment in this merchandise. For instance, in 2024, biosimilar guidelines imposed by the EMA accelerated the IAC demand with €2.6 billion funding for biomanufacturing. The emerging nations, such as Germany, France, the U.K., Italy, and Spain, are at the forefront of propelling engagement, adoption, and development in the region.
France is propagating in the regional immunoaffinity chromatography market with a collective goal to take leadership in the gene therapy sector. In this regard, the country holds a 26.4% share in the Europe market, crucially facilitated by Sanofi’s gene therapy investments and 8.3% healthcare budget allocation towards IAC. The country also witnesses exponential growth, benefiting from Europe’s biomanufacturing fund. Furthermore, the HAS’s current guidelines expanded reimbursement for IAC-based diagnostics, solidifying its significance across the country’s vast geography.
